The thiopeptide class of antibiotics targets the GTPase-associated center (GAC) of the ribosome to inhibit translation factor function. Using X-ray crystallography, we have determined the binding sites of thiostrepton (Thio), nosiheptide (Nosi), and micrococcin (Micro), on the Deinococcus radiodurans large ribosomal subunit. The thiopeptides, by binding within a cleft located between the ribosomal protein L11 and helices 43 and 44 of the 23S rRNA, overlap with the position of domain V of EF-G, thus explaining how this class of drugs perturbs translation factor binding to the ribosome. The presence of Micro leads to additional density for the C-terminal domain (CTD) of L7, adjacent to and interacting with L11. The results suggest that L11 acts as a molecular switch to control L7 binding and plays a pivotal role in positioning one L7-CTD monomer on the G 0 subdomain of EF-G to regulate EF-G turnover during protein synthesis.
INTRODUCTION
The protein-synthesizing apparatus, the ribosome, is one of the major targets in the cell for natural antibiotics (reviewed by Spahn and Prescott, 1996; Wilson, 2004) . In the past 7 years, significant progress has been made in the determination of structures of ribosomal subunits in complex with many of the major classes of antibiotics (reviewed by Wilson, 2004) . These structures have provided insight into the mechanism of action of antibiotics, revealing that they bind almost exclusively to ribosomal RNA (rRNA) and target the active sites of the prokaryotic ribosome, such as the decoding site on the 30S subunit and the peptidyltransferase center on the 50S subunit. However, another important region for ribosome function is the ''factor binding site,'' which encompasses the so-called GTPase-associated center (GAC), responsible for binding and stimulation of the GTPase activity of translation factors from all phases of translation. Unlike other active sites, the GAC is rich in ribosomal proteins (r-proteins) as well as rRNA. Three GAC components considered to be important for GTPase activation of translation factors include (1) the sarcin-ricin loop (SRL) located in helix 95 (H95) of the 23S rRNA; (2) the ribosomal stalk, composed of r-proteins L10 and 4-6 copies of L7/L12; and (3) the stalk base (SB), comprising L11 and its binding site on the 23S rRNA, namely H43 and H44 (reviewed by .
The thiopeptide family includes some of the best studied antibiotics in the field of translation, such as thiostrepton (Thio) and micrococcin (Micro), as well as the lesser known nosiheptide (Nosi) (reviewed by Spahn and Prescott, 1996; Wilson, 2004) . These antibiotics bind the SB and, unlike most other antibiotics, target both r-protein (L11) as well as (23S) rRNA. The cooperative nature of the binding is highlighted by the fact that Thio cannot bind free L11 (Highland and Howard, 1975; Porse et al., 1998) , and, although it can bind naked 23S rRNA, the affinity is much lower ($10 3 ) than that for the intact ribosome (Bausch et al., 2005; Thompson et al., 1979) . Moreover, resistance to Thio and Micro can be obtained by deletion or mutations in the rplK gene encoding L11 (Cameron et al., 2004; Cundliffe et al., 1979; Porse et al., 1998 Porse et al., , 1999 Wienen et al., 1979) , as well as transversions and transitions of A1067 or A1095 (Escherichia coli numbering is used throughout) in H43 or H44, respectively, of the 23S rRNA (Cameron et al., 2004; Hummel and Boeck, 1987; Mankin et al., 1994; Rosendahl and Douthwaite, 1993) .
Of the thiopeptides, the effect of Thio and Micro on the action of EF-G has been most intensively studied (Bowen et al., 2005; Cameron et al., 2002; Lentzen et al., 2003; Rodnina et al., 1999; Seo et al., 2004 Seo et al., , 2006 . Traditionally, Micro has been documented as a stimulator of the GTPase activities of EF-G (Cameron et al., 2002) while Thio is considered a factor-specific translocation inhibitor that prevents the EF-G-catalyzed movement of the A and P tRNAs (PRE state) to the P and E sites (POST state) of the ribosome (Cameron et al., 2002; Lentzen et al., 2003) . The differential effect of Thio and Micro on EF-G GTPase is intriguing, as the two drugs have similar structures and are expected to bind in the same region of the ribosome.
The low solubility of thiopeptides led to the difficulty in the use of these compounds within the clinical setting; however, there has been renewed interest due to (1) the discovery of fragments of Thio that have biological activity (Nicolaou et al., 2005a) , (2) a complete description for the total synthesis of Thio now being available (Nicolaou et al., 2005b) , and (3) the finding that both Thio and Micro inhibit not only bacteria, but also the growth of the human malarial parasite Plasmodium falciparum by acting on the ribosomes of the plastid-like organelle (Rogers et al., 1998) . However, development of more potent thiopeptide inhibitors requires a better structural understanding of how these compounds interact with ribosome to exert their differential effects of factor-dependent GTPase activities.
In this study we have determined the binding sites of the thiopeptides Thio, Nosi, and Micro on the Deinococcus radiodurans large ribosomal subunit. All three thiopeptides bind within a cleft located between the L11-NTD and the loops of H43 and H44 of the 23S rRNA, in good agreement with the wealth of available biochemical data related to these compounds. Unexpectedly, the binding of Micro leads to the appearance of density for one C-terminal domain (CTD) of r-protein L7/L12 (L7-CTD). The L7-CTD contacts L11 and is located in the same relative position as additional density assigned to L7-CTD in our recent cryoelectron microscopy (cryo-EM) reconstruction of EF-G bound to a 70S ribosome (Connell et al., 2007) . Coupled with the stimulatory effect that Micro, but not Thio or Nosi, has on EF-Gdependent GTPase, this leads us to present a model whereby two molecular switches are present in L11 that play a pivotal role during translation elongation to position one of the L7-CTD to interact with the G 0 subdomain of EF-G, and thus promote rapid and efficient EF-G turnover during protein synthesis.
RESULTS
The Binding Position of the Thiopeptide Antibiotics on the Ribosome Data sets from crystals of the D. radiodurans large ribosomal subunit (D50S) in complex with the thiopeptide antibiotics Thio, Nosi, and Micro were collected at a resolution of 3.3-3.7 Å (Table  1) . Thio comprises 16 chemical moieties that can be grouped into two loops and a tail ( Figure 1A ). While the first loop is conserved in both Nosi and Micro, loop2 is shorter (and connected differently) in Nosi, and totally absent in Micro ( Figures 1A-1C) . In each reconstruction obtained, the electron density for the L11-NTD was significantly improved compared to the native D50S and additional ring-like density, which was attributed to the drug, was observed in a cleft between the L11-NTD and the tips of H43 and H44 of the 23S rRNA ( Figure 2A ). The availability of small-molecule structures of Thio (Bond et al., 2001) and Nosi (Prange et al., 1977) enables an accurate fitting of the drug structure to the density for these two compounds ( Figures  2B and 2C) .
The density for Micro indicates that the drug does not bind in the same position as Thio or Nosi, with loop1 being displaced by $6 Å when compared to Thio ( Figure 5B ). The resolution limitations and absence of a 3D small-molecule structure for Micro prohibited precise determination of the molecular interactions. Nevertheless, we generated a model for Micro based on the similarities between Micro and Nosi ( Figures 1B and 1C) , which serves as a placeholder for the position of the drug, and allows the differential activities of Micro with respect to Thio to be elucidated. 
Interaction of Thio and Nosi with the Ribosome
The interaction of Thio and Nosi with the ribosome is predominantly hydrophobic, analogous to the binding of the lactone rings of the macrolide class of antibiotics (Hansen et al., 2002) . Consistent with the conservation of loop1 in the Thio and Nosi structures ( Figures 1A and 1B) , this loop inserts into the cleft between L11-NTD and the 23S rRNA, and constitutes the predominant interactions between the drug and the ribosome. Loop2 moieties, with the exception of the quinaldic acid (QA) group, which approaches H44, are solvent exposed. Accordingly, of the 620 Å 2 of surface that Thio buries on the ribosome, 60% are attributable to loop1 residues, whereas the tail and loop2 contribute 26% and 14%, respectively. The sulfur-containing thiazole rings in loop1 and the tail, which give this class of antibiotic its name, are positioned to stack on either the bases of RNA nucleosides or the aromatic side chains of amino acids in the L11-NTD. (However, it should be noted that the geometry is not optimal for Pi-stacking interactions, so stacking is used in a more generic sense here.) In particular, THZ6 and THZ14 of Thio (refer to Figure 1 for the different moieties of the drug) stack on Pro22 and Pro26 of L11, respectively, while THZ1 is oriented to form stacking interactions with A1095 of the 23S rRNA (Figures 3A and 3B) . It has been suggested that the QA moiety of Thio is engaged in Pi-stacking interaction with the base of A1067 (Lentzen et al., 2003) ; however, although the QA moiety approaches A1067 in the structure, the orientation, geometry, and distance preclude any significant stacking interaction. The QA moiety of Thio does, however, come within 3.5 Å of the N1 of A1067, explaining why Thio protects this position from chemical attack by dimethylsulfate (DMS) (Bowen et al., 2005; Egebjerg et al., 1989; Rosendahl and Douthwaite, 1993) . The THZ1 ring of Thio stacks onto the base of A1095 and comes within 3.5 Å of the N7, whereas the neighboring residues (THR2 and DHB3) in loop1 approach within 4 to 5 Å of the N1 of A1095, consistent with protection by Thio of these positions from chemical probing using diethylpyrocarbonate and DMS, respectively (Egebjerg et al., 1989) .
Superimposing the small-molecule structure of Thio, on the basis of loop1, positions the tail of the drug extending out into the solvent such that no contacts with the ribosome are possible ( Figure 3C ). However, in the bound state, the tail of Thio is reoriented compared to the small-molecule structure, reaching over alpha-helix 1 (a1) in the L11-NTD and contributing significantly to the overall interaction area (26%). This placement of the tail seems to induce a conformational change in L11 so that the position of both a1 as well as the distal end (N-terminal b strand [b1] and loop between b2 and b3) of L11-NTD are shifted relative to their position in the native D50S structure ( Figure 3D ). Interestingly, a similar conformational switch in the L11-NTD is observed when Nosi binds to the D50S ( Figure 3E ). In this case, however, the tail of Nosi runs parallel to a1 passing under Gln30, rather than reaching over it as Thio does. Nevertheless, Nosi apparently induces a similar shift in L11-NTD by encroaching on the position that a1 normally occupies in the native D50S structure.
Consistent with the conformational switch observed in this region, the presence of Thio has been shown to protect Tyr62, located in the loop between b2 and b3, and to a lesser extent Phe38 (a2) and Phe67 (b3) from chymotrypsin cleavage (Porse et al., 1998) .
As well as being consistent with the biochemical data, the binding position of Thio determined here crystallographically is in good agreement with a model for the loop1 and loop2 moieties of Thio produced by Lentzen and colleagues from NMR restraints (Lentzen et al., 2003) . However, the exact placement of Thio differs slightly from the NMR model: when aligning the two structures on the basis of H43 and H44 (rmsd, 1.3 Å ) the position of Thio is shifted (3 to 4 Å ), leading to slight changes in the interaction with the ribosome, such as the aforementioned stacking between the QA moiety of Thio and the base of A1067. The interaction between Thio and the rRNA as seen in the more recent NMR-derived model (Jonker et al., 2007) exhibits also some differences (see Figure S1 available online) with respect to the structure presented here, which may result from the fact that a mutant rRNA fragment was used for H43/44.
Thiopeptide Resistance in Prokaryotes and Eukaryotes
Mutations at position A1067 in H43 or A1095 in H44 confer resistance to Thio in E. coli (Rosendahl and Douthwaite, 1994; Thompson et al., 1988) . Both adenines are conserved in all prokaryotic 23S rRNA sequences ( Figure S2 ), and mutations of the equivalent positions in Thermus thermophilus (Cameron et al., 2004) , and A1067U/G mutations in the archaea Halobacterium halobium and H. cutirubrum (Hummel and Boeck, 1987) , also confer Thio resistance. The tertiary structure of H43 and H44 in the D50S is essentially identical to that observed in E. coli (Schuwirth et al., 2005) and Haloarcula marismortui (Ban et al., 2000) ribosome structures, as well as the L11-RNA complex from Thermotoga maritima (Wimberly et al., 1999) . Therefore it is likely that Thio binds in a similar fashion to all prokaryotic ribosomes and that the mechanism of resistance is analogous.
The Thio-D50S structure presented here reveals that A1067 and A1095 in H43 and H44 make the most extensive contact with the drug, with the only other significant interaction involving the ribose of G1068. A1067 and A1095 are located at the tips of their respective helices and form a platform upon which Thio sits (Figures 2A and 3A) . Footprinting experiments demonstrate that mutation of A1067 or A1095 to a pyrimidine (U or C) reduces Thio binding (1000-fold as measured by monitoring the protection of A1095) more effectively than the A1067G purine transversion (Rosendahl and Douthwaite, 1994) . Furthermore, a 3-fold excess (40 nM) of Thio over ribosomes can inhibit EF-G-dependent GTP hydrolysis on wild-type (60%) and A1067G (21%), but not on A1067U ribosomes (Cameron et al., 2004) . Indeed, for the A1067 mutations, a correlation between the loss in Thio binding and the level of Thio resistance has been previously observed (Thompson et al., 1988) . In the Thio-D50S structure, a pyrimidine at either A1067 or A1095 would provide less surface area for stacking or hydrophobic interactions than a purine, providing a possible explanation for how such mutations would reduce the affinity of Thio to confer higher levels of resistance. However, conformational changes within the loop structures induced by these mutations that prevent or reduce drug binding cannot be ruled out. The producer of Thio, Streptomyces azureus, inhibits drug binding to its own rRNA by 2 0 -O-methylation of position A1067 (Thompson et al., 1982) . The 2 0 O of A1067 is within 3.1 Å of the THZ4 ( Figure 3B) , and therefore the presence of an additional methyl group would prevent the close approach of loop1 of Thio to H43, analogous to mechanism by which (di)methylation of the N6 of A2058 confers resistance to macrolides such as erythromycin (Hansen et al., 2002 as well as explaining the cooperative nature of rRNA and L11-NTD for Thio binding (Xing and Draper, 1996) . It is also possible to rationalize how point mutations within the L11-NTD confer varying degrees of Thio resistance (Cameron et al., 2004; Porse et al., 1998 Porse et al., , 1999 . The thiazole rings THZ6 and THZ14 of Thio ( Figure 1A ) stack upon Pro22 and Pro26, respectively, within L11-NTD, and therefore mutations, for example to Ser, Leu, or Arg at these positions, or deletion of neighboring residues Ala20-Pro21 could abolish this type of interaction. More likely is that the mutations have a global (and long-range) influence on the conformation of the L11-NTD by disrupting the prolinerich helix a1, explaining why mutations at Pro23 can also confer resistance, even though this residue does not come within 7 Å of Thio ( Figure 3B ). Interestingly, in eukaryotic organisms many of the Pro residues are not conserved ( Figure S3) ; specifically, Pro22, Pro23, and Pro56 are usually Ser, Ala, or Thr at the equivalent positions. Because mutations at positions Pro22 and Pro23 (to Ser or Thr) as well as Pro56 (to His) confer resistance to Thio in various bacteria (Cameron et al., 2004) , the natural thiopeptide resistance of eukaryotes can be explained by presence of Ser, Ala, and Thr at these positions. However, it should be noted that 90%-98% of known eukaryotic 23S rRNA sequences also contain a guanine at the position equivalent to E. coli A1067 ( Figure S2 ), and as mentioned above A1067G mutations confer Thio resistance in bacteria and archaea. Thus eukaryotes can be considered to be ''doubly'' protected through the presence of rRNA as well as protein differences.
Interrelationship between Thio, Nosi, L11, and EF-G on the Ribosome We have recently determined a 7.3 Å cryo-EM reconstruction of T. thermophilus 70SEF-GGDPNP complex (Connell et al., 2007; Figures 4A and 4B) . The subnanometer resolution enables secondary structure elements to be identified in the electron density corresponding to EF-G and r-proteins, which greatly aids the docking of X-ray structures. Of particular interest for this study, the cryo-EM map reveals continuous density between EF-G and components of the stalk base (SB), implying an interaction whereby a helix A 5 in domain V of EF-G approaches the SB cleft formed by H44, and the b strand 2 5 potentially interacts with H43 and the proline-rich a1 of the L11-NTD (Figures 4C and  4D ). The latter interaction is consistent with the strong protection of A1067 from DMS probing upon binding of EF-GGDPNP to the ribosome (Moazed et al., 1988) . Moreover, this is also in agreement with the reported crosslink between EF-G and rRNA in the vicinity of A1067 (Skold, 1983) , as well as the dramatic reduction that A1067C mutations have on uncoupled EF-G-dependent GTPase activity (Cameron et al., 2002) . Additionally, site-directed hydroxyl-radical probing from residues located in domain V of EF-G results in cleavage within the loops of H43 and H44 (Wilson and Noller, 1998) .
The mechanism by which thiopeptides inhibit EF-G action can be understood by aligning the D50S-thiopeptide and 70SEFGGDPNP structures on the basis of H43 and H44, revealing an extensive overlap between Thio ( Figure 4D ) or Nosi (data not shown) and EF-G. Thio sterically clashes with EF-G by mimicking to some extent regions of domain V, i.e., loop1 of Thio approaches the position of EF-G b strand 1 5 while loop1 and the QA moiety of loop2 superimpose with the antiparallel EF-G b strands 2 5 and 3 5 , respectively ( Figure 4D ). Additionally, the interaction of the tail of Thio/Nosi appears to further fix the position of L11 with respect to the SB. This arrangement of L11 is dramatically different than that seen in the 70SEFGGDPNP complex, where EF-G binding seems to displace the L11-NTD so that the cleft widens compared to that seen in the Thio/Nosi structure ( Figure 4D ). In this regard not only would Thio compete with EF-G, but it would lock the L11-NTD in a position such that it also contributes to preventing stable interaction between EF-G and the SB. Figure 4D illustrates that if the L11-NTD were to be fixed as seen in the D50S-thiopeptide structure, then the a1 of L11-NTD would come too close to the b strand 1 5 of domain V of EF-G. The strong overlap between Thio and EF-G is consistent with reports that Thio abolishes the binding of EF-G to the 70S ribosome (Cameron et al., 2002) , as well as more indirect evidence showing that Thio reduces crosslinking of EF-G to the ribosome (for example, see Skold, 1983) . A model for the biologically active dehydropiperidine (DHP) core fragment of Thio (inset to Figure 1A ; Nicolaou et al., 2005a) bound to the ribosome suggests that DHP, like Thio, also locks the L11-NTD to the rRNA ( Figure 4E ), lending support to the importance of this feature of thiopeptides for their inhibitory action.
Conflicting reports based on fast kinetic and FRET studies, however, indicate that Thio does not inhibit binding or GTP hydrolysis, but instead prevents translocation, inorganic phosphate (Pi) release, and multiple turnover by trapping the factor on the ribosome (Pan et al., 2007; Rodnina et al., 1999; Seo et al., 2006) . We believe that these results can be reconciled if one considers that Thio does not prevent binding of EF-G per se, but precludes formation of a tight complex that can be monitored by centrifugal binding assays (Cameron et al., 2002) while allowing a weak binding that can be detected indirectly by the time-resolved studies (Rodnina et al., 1999; Seo et al., 2006) . Indeed, Thio has been demonstrated to produce a 10-fold decrease in EF-GGDPNP binding to 70S ribosomes by slowing the initial binding and preventing the conversion from a weaker initial complex to a subsequent stable complex (Pan et al., 2007; Seo et al., 2004) . The SB has been shown to adopt two positions on the ribosome, the ''in'' and ''out'' conformations (Schuwirth et al., 2005) , with the inward shift occurring when translation factors, such as EF-G, are loaded onto the ribosome (see Spahn et al., 2004 and references therein). In Figure 4F , it can be seen that the overlap between Thio and domain V of EF-G is significantly reduced when Thio is modeled onto the SB adopting an out position on the ribosome. This suggests that the initial weak binding of EF-G may represent a state before the SB has moved inwards and tight interactions are formed between H43/44 and domain V of EF-G. Thio would allow this initial interaction and apparently permits GTPase activation, but by restricting access to the cleft between L11-NTD and H43/44, Thio prevents the conformational changes in the ribosome (i.e., in the SB) and EF-G that are required for translocation.
Micro Promotes the L11-L7/L12 Interaction
As mentioned above, the density for Micro indicates that the drug does not bind in the same position as Thio/Nosi, with loop1
Molecular Cell
Translational Regulation via L11 (Connell et al., 2007) , with fitted crystal structures for EF-G (green; PDB 1FMN), L7-CTD (magenta), and D50S L11 (yellow). The cryo-EM density (gray surface) has been low-pass filtered to 12 Å to strengthen features, such as the stalk and the L11-NTD, which are disordered in the cryo-EM map at 7.3 Å . However, the shown molecular models were docked into the cryo-EM map at full resolution (7.3 Å ). being displaced by $6 Å when compared to Thio (Figures 5A and  5B ). In the model, the tail of Micro appears to interact with A1095, but the drug does not seem to approach A1067 to the same extent as Thio/Nosi ( Figure 5B ). This is consistent with the fact that mutations at A1095 confer better resistance to Micro than transversions and transitions at A1067 (Rosendahl and Douthwaite, 1994) , and is also in agreement with the observation that Micro enhances the chemical reactivity of A1067, rather than protecting it as Thio does (Egebjerg et al., 1989; Rosendahl and Douthwaite, 1993) .
Unlike Thio (and Nosi), Micro has been shown to stimulate uncoupled EF-G-dependent GTPase activity (Cameron et al., 2002; Lentzen et al., 2003) . Consistent with these differential effects, a number of differences are apparent in the crystal structures. First, the conformation of Micro-L11 is similar to that of L11 in the native D50S structure, and thus the conformational switch observed in the distal region of the L11-NTD, as is observed upon Thio/Nosi binding to the D50S, is not induced by Micro. Second, additional density appears adjacent to L11-NTD in the D50S-Micro structure, which is not present in the Thio/Nosi structures. This density can be modeled as the CTD of L7/L12 (L7-CTD; residues 52-122), allowing the interaction interface between L11-NTD and L7-CTD to be defined. The interaction surface comprises two main regions of L11-NTD, namely, the loop between b2 and b3 that inserts into a crevice between a4 and a6 of L7-CTD, and the N terminus of L11, which makes additional contacts to the proximal end of a4 ( Figure 5C ). In the native D50S structure, the density for the L11-NTD is relatively poor due to its apparent flexibility; however, the predominant conformation of the NTD appears to be almost identical to Microbound L11-NTD, and careful reinspection reveals additional density, albeit weaker, which is consistent with the presence of L7-CTD in the same position as observed in the Micro structure (data not shown). These results suggest that the interaction observed in the Micro-D50S structure between L11 and L7 is indeed ''physiological'' because it also occurs on native ribosomes, and that the presence of Micro stabilizes this interaction. In contrast, the conformational switch introduced in the L11-NTD by Thio/Nosi would prevent the L7-L11 interaction, which likely contributes to the different inhibitory effect of these drugs ( Figure 5D ).
Previous cryo-EM studies on the 70SEF-GFusGDP complexes (Datta et al., 2005) also support an interaction between L7 and the distal tip of L11-NTD; however, the relative arrangement of L11 and L7 differs from our study ( Figure S4 ). When aligning the L11-NTDL7-CTD complex from the Micro-D50S structure to the 70SEFGGDPNP cryo-EM reconstruction (Connell et al., 2007) , the position of L7-CTD correlates with the fragmented density attributed to L7/L12 in the cryo-EM structure ( Figure 5E ). In this orientation, the a4 and a5 helices of L7-CTD face toward two a helices, A G and particularly B G , located in the G 0 subdomain of EF-G. This interaction surface is consistent with the complementarities of these two surfaces in terms of electrostatic potential ( Figure S5 ), as well as the large number of highly conserved residues that project toward EF-G from the a4-a5 surface of L7-CTD. Moreover, NMR studies implicate many of these conserved residues, namely Val66-Val68, Lys70, Leu80, and Glu82, in forming direct interaction with EF-G ( Figure 5F ) (Helgstrand et al., 2007) , and mutations of residues in helix a4 (Val66, Ile69, Lys70 and Arg73) strongly inhibit Pi release without affecting single turnover GTPase or translocation functions of EF-G ( Figure 5G) (Savelsbergh et al., 2005) .
In accordance with previous biochemical studies (Cameron et al., 2002; Lentzen et al., 2003) , we suggest that Micro stimulates the uncoupled GTPase of EF-G by stabilizing the L11-L7 interaction and in doing so pre-positions L7 for interaction with EF-G. Once positioned on EF-G, L7 would stimulate EF-G turnover by promoting Pi release in accordance with fast kinetic studies (Diaconu et al., 2005; Savelsbergh et al., 2005) .
DISCUSSION
In this study we used X-ray crystallography to elucidate the binding sites of Thio, Nosi, and Micro on the large ribosomal subunit. These results have been further analyzed within the context of a cryo-EM reconstruction of a 70SEFGGDPNP complex that we have previously reported (Connell et al., 2007) .
A comparison of these structures reveals a critical point on the ribosome in the region of L7 and L11 that adopts different conformations depending on the type of ligand present. Specifically, the ligands seem to control two molecular switches in the ribosomal protein L11, which, by changing its conformation on the ribosome, creates different scenarios, as follows.
The first switch in L11, Switch 1, is an interdomain event analogous to the switch proposed to exist on the basis of the flexibility of the L11-NTD (Porse et al., 1998; Wimberly et al., 1999) . Switch 1 involves the displacement of the L11-NTD with respect to the L11-CTD and controls the widening and closure of the cleft present at the SB between the L11-NTD and H43/44 of the rRNA (the switch between the ''off'' and ''on'' positions is arrowed in Figure 4D ). Switch 1 is stabilized in the on position upon EF-G binding, such that the open conformation allows proper insertion and accommodation of domain V of EF-G within the cleft of the SB ( Figure 4C ). In contrast, the Thio/Nosi-D50S structures reveal that the drugs, by interacting with both H43/44 and L11-NTD, lock Switch 1 in the off position by restricting the L11-NTD movement that leads to cleft widening ( Figure 4D ).
The second switch in L11, Switch 2, is an intradomain event that involves a conformational change within L11-NTD, such that in the on position, a complementary surface is formed to promote a stable interaction between L11-NTD and L7-CTD (Figure 5D) . Switch 2 is observed in the off position in the presence of Thio and Nosi, while with Micro and in the 70SEFGGDPNP complex, Switch 2 is in the on position. In the latter case, the interaction between the L11-NTD with the L7-CTD positions the L7-CTD in close contact with the G 0 subdomain of EF-G ( Figure 5E and Figure S5 ). . In particular, the density allows accurate placement of a4, a5, and a6 of L7-CTD.
When these results are taken within the context of our current knowledge of the elongation cycle, it is possible to revisit the sequence of events controlled and triggered on the ribosome by EF-G. Figure 6 provides a model for the role played by the two molecular switches identified in L11 as well as rationalizes the specific inhibitory effects of the thiopeptide class of antibiotics. The details of the model are as follows.
Cryo-EM reconstructions (Frank and Agrawal, 2001; Li et al., 2006; Spahn et al., 2004; Valle et al., 2003) reveal that as elongation factors are loaded onto the ribosome, the SB oscillates between ''out'' and ''in'' positions (Figures 6A and 6B) . In the case of EF-G, this transition is accompanied by the hydrolysis of GTP that has been shown to occur as soon as EF-G interacts with the ribosome ( Figure 6A )-in contrast to the release of Pi and translocation, which are much slower steps (Rodnina et al., 1999; Seo et al., 2004 Seo et al., , 2006 Savelsbergh et al., 2005) , facilitated by the involvement of L7/L12 (Savelsbergh et al., 2005) . In this respect, the activation of both molecular switches identified in L11 plays an important role: first, turning on Switch 1 ensures the proper insertion and accommodation of domain V of EF-G into the widened cleft present at the SB ( Figure 6B ); and second, Switch 2 promotes a stable interaction of the L7-CTD with the L11-NTD, such that L7-CTD is optimally positioned to contact the G 0 subdomain of EF-G ( Figure 6C ). L7 has been shown to be important for stimulating Pi release, but not GTP hydrolysis per se (Savelsbergh et al., 2005) , suggesting that the interaction of the L7-CTD with the G 0 subdomain of EF-G will trigger conformational changes within the GTP-binding pocket of EF-G to allow Pi release ( Figure 6D ).
In the model described above, Thio and Nosi seem to interfere at two different levels:, First of all, the thiopeptide-D50S structures reveal that the drugs, by interacting with both H43/44 and L11-NTD, block the Switch 1 event in L11 ( Figure 6B ) by restricting the L11-NTD movement that leads to the widening of the cleft, and thus prevent EF-G from entering the cleft and stably interacting with the SB (Figure 6E ). This is consistent with the more labile initial binding state of EF-G on the ribosome observed in the presence of Thio (Seo et al., 2006) . Moreover, the structure of Thio/Nosi bound to the D50S reveals that these drugs also interfere with EF-G action at the Switch 2 level; both Thio and Nosi divided into with N-and C-terminal domains (NTD, CTD) and rRNA helices H43 and H44 (blue). The C-terminal domain of L7 (L7-CTD) is shown in red. Note that for simplicity, the switching mechanism has been divided into two distinct steps; however, it is unclear as to whether they are sequential, as shown here, or occur simultaneously.
(D) Comparison of the conformations of L11 bound to different thiopeptides with respect to L7-CTD. The L11-NTD bound with Thio (Thio-L11; cyan), Nosi (Nosi-L11; green) and Micro (Micro-L11; yellow) was aligned on the basis of H43 and H44. Unlike Micro, Thio and Nosi induce conformational change in L11-NTD that leads to steric clashing between the N terminus of L11 and a4 of L7-CTD.
(E) The relative positions of the L11-L7 complex with respect to EF-G. The L7-L11 (L7, magenta; L11, yellow) complex from the Micro-D50S structure was aligned to the cryo-EM reconstruction of the 70SEF-GGDPNP map (Connell et al., 2007) using the L11-NTD. L11-NTD, L7-CTD, and EF-G from the cryo-EM structure are shown in orange, blue, and green, respectively, with cryo-EM density in gray filtered to 14 Å . stabilize the structure of the L11-NTD in the ''off'' position, i.e., inducing a conformational change within the L11-NTD that perturbs the L11-L7 interaction surface. This in turn prevents binding of L7-CTD to L11 ( Figure 6E ), thus explaining the reduction in Pi release observed in the presence of these drugs (Cameron et al., 2002; Lentzen et al., 2003; Rodnina et al., 1999; Seo et al., 2004 Seo et al., , 2006 . In contrast to Thio and Nosi, Micro has been shown to stimulate, rather than inhibit, the uncoupled EF-G-dependent GTPase activity of the ribosome (Cameron et al., 2002; Lentzen et al., 2003) . Accordingly, in the crystal structure of the large ribosomal subunit in complex with Micro, we observe a different situation, in which Micro (1) displays a different interaction with rRNA of the SB, although it would still prevent the Switch 1 event by restricting the interdomain movement in L11; (2) fails to invoke the intradomain conformational changes seen within the L11-NTD of the Thio/Nosi structures; but instead (3) turns Switch 2 ''on'' by promoting or stabilizing the interaction between L11 and L7-CTD ( Figure 6F ). Micro may therefore function to stimulate the uncoupled GTPase of EF-G by stabilizing the L11-L7 interaction and thus pre-positioning L7 on L11 so that it can interact with EF-G. Once positioned on EF-G, L7 would constantly stimulate GTP turnover by promoting Pi release in accordance with biochemical studies (Cameron et al., 2002) . This indicates that turning Switch 2 on can occur independently of Switch 1 activation, and does so at least in the case of Micro.
Therefore, we suggest that the double-switching mechanism identified in L11 acts as a molecular sensor to monitor and control the translational state of the ribosome, allowing the functional complex to move from the labile initial binding state of EF-G to its stable accommodated state and then forward to the low-affinity EF-G dissociation state that occurs upon Pi release. The presence and conservation of the two-domain structure of L11 throughout all kingdoms of life suggests that this double-switching mechanism may be universal.
EXPERIMENTAL PROCEDURES
Crystallography D. radiodurans large ribosomal subunit crystals were prepared as described (Schlü nzen et al., 2001 ) and soaked in a cryosolution containing 20-40 mM thiopeptide (Thio, Micro, or Nosi) for 12-24 hr, prior to freezing. Data were collected at 100 K from shock-frozen crystals at X06SA at Swiss Light Source (SLS), Villigen, Switzerland and ID29 at ESRF (Grenoble, France). Data were recorded on MAR345 or Quantum 4 detectors and processed with HKL2000 (Otwinowski and Minor, 1997) and the CCP4 package (CCP4, 1994).
Modeling and Docking
The native structure of the D50S subunit and PDB 2ZJR) was refined against the structure factor amplitudes of the D50S-thiopeptide antibiotic complexes, using rigid body refinement as implemented in CNS (Brunger et al., 1998) . For the calculation of the free R factor, 5% of the data were omitted during refinement. The positions of the thiazole antibiotics H43, H44, L11, and L12-CTD were determined from sigma-weighted difference maps or composite omit maps followed by density modification and phase recombination as described in Diaconu et al. (2005) . Further refinement was carried out using CNS (see Table 1 for refinement statistics).
The D50S-thiopeptide antibiotic interactions were originally determined with Chimera (Pettersen et al., 2004) . Alignment of the 70SEF-GGDPNP complex (Connell et al., 2007) and the Thio-SB model (PDB 1OLN; Lentzen et al., 2003) was performed by least square alignments of H43-44 onto the D50S structure ). The starting model for refinement of the L7-CTD was based on a homology model for D. radiodurans L7-CTD generated using the Protein Homology/analogY Recognition Engine (PHYRE) (http://www.sbg. bio.ic.ac.uk/$phyre/) with the crystal structure for T. maritima L7 (PDB 1DD3; Wahl et al., 2000) as a template. Electrostatic potentials were calculated using the program APBS (Baker et al., 2001) , and buried surface area was calculated with AREAIMOL in the CCP4 package (CCP4, 1994).
Coordinates and Figures
All crystallographic figures were produced using PyMOL (http://www. pymol.org).
ACCESSION NUMBERS
Final coordinates and structure factors for native-D50S, Thio-D50S, Nosi-D50S, and L7-CTD-D50S (Micro) have been deposited in the Protein Data Bank under accession numbers 2ZJR, 3CF5, 2ZJP, and 2ZJQ, respectively.
SUPPLEMENTAL DATA
Supplemental Data include five figures and Supplemental References and can be found with this article online at http://www.molecule.org/cgi/content/full/ 30/1/26/DC1/.
